Menu
Recruiting NCT06204315

Risk Adapted Spinal Cord/Cauda Constraint Relaxation for High-risk Patients With Metastatic Epidural Spinal Cord Compression Undergoing Spine Stereotactic Radiosurgery

Phase II Interventional Spinal Cord Metastatic Epidural Spine Stereotactic

For patients and families

In plain language

An automatic summary of structured registry data. It is an orientation aid, not a substitute for the official protocol or a physician assessment.

What is being studied
The protocol lists: Stereotactic Radiosurgery.
Who it may be relevant to
Registry conditions: Spinal Cord, Metastatic Epidural, Spine Stereotactic. Basic parameters: from 18 years · All.
What needs checking
Age, condition and sex are only basic indicators. Prior treatment, laboratory values and other mandatory requirements appear in the eligibility criteria below.
Where it takes place
United States
Next step
Save the trial, show it to the treating physician, and confirm current recruitment with the study center. Costs, documents and travel →

Overview

To learn about the safety of a procedure called cord dose escalated spine stereotactic radiosurgery (CDE-SSRS) in patients with MESCC.

Detailed description

Primary Objectives The primary protocol objectives are to establish the safety of CDE-SSRS alone in participants with MESCC. Specifically, we aim to maintain an RM risk no greater than 1%. RM will be defined as non-functional paresis per the McCormick score (i.e., Grade D).

Secondary Objectives Secondary objectives include pain control as measured by the Brief Pain Inventory, quality of life as measured by the EQ-5D, symptom burden as measured by the MDASI-SP, overall survival, toxicity, ambulatory rate and cost-effectiveness. LC will be defined radiographically with serial MRI scans by the study radiologist per SPINO criteria.

Interventions

  • Radiation Stereotactic Radiosurgery
    Given by RTx

Primary outcome measures

  • Safety and adverse events (AEs) [Time frame: Through study completion; an average of 1 year.]

Eligibility criteria

Inclusion criteria

  • Greater than or equal to 18 years old
  • Radiographically documented spinal metastasis on spine MRI within 4 weeks of registration
  • Proximity of spinal metastasis to spinal cord or cauda equina which precludes achieving a GTV Dmin of at least 14 Gy per the PI
  • All participants must be able to receive single fraction SSRS at the site of interest with 0.01 cc of the spinal cord receiving 14-16 Gy and/or 0.01 cc of the cauda equina receiving 18-20 Gy. The goal of treatment is to select the minimal dose to the organ at risk which will achieve a GTV Dmin of 14 Gy at the treating physician's discretion.
  • Maximum of 3 contiguous vertebral levels involved with metastasis in the spine to be irradiated in a single session
  • All participants must be able to receive a single fraction spine radiosurgery at the designated site of interest to at least a dose of 18 Gy
  • All participants must have a vertebral level site of interest from C1 to S2
  • Signed informed consent
  • Diagnosis of cancer excluding ultra-radiosensitive histologies (see 4.2)
  • Motor strength ≥ 4 out of 5 in extremity or extremities affected by the level of cord compression
  • ECOG ≤ 2

Exclusion criteria

  • Participants with ultra-radiosensitive histologies (lymphoma, multiple myeloma/plasmacytoma)
  • Prior history of radiation at the spinal site of interest
  • Inability to lie supine comfortably for ≥ 60 minutes
  • Progressive neurological deficits due to compression
  • Inability of obtain an MRI
  • Inability or refusal to undergo an MR simulation
  • No eligible for single fraction SSRS for any reason
  • Participants who are pregnant

Criteria are shown verbatim from the registry (in English). Final eligibility is always assessed by the study center.

Healthy volunteers: No

Study design

Allocation
N/A
Model
Single group
Masking
Open label
Primary purpose
Supportive care

Study locations

United States · 1 center
  • MD Anderson Cancer Center — Houston

Identifiers

NCT: NCT06204315 · 2023-0287 · NCI-2024-00049

Primary sources (government registries)

View this study on ClinicalTrials.gov ↗